阿奇夫生命科学
ACHV
6.38
-0.59
-8.46%
阿奇夫生命科学
US · ACHV
#3471 按市值排名
6.38
-0.59
-8.46%
实时 - 追踪5344个代码 - 心跳于279秒前
· 2026-10-16 19:43
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量增加了2家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 85.56% +0.06pp
- 机构数量
- 131 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund35.22%
VC/PE Fund25.18%
Hedge Fund23.30%
Individual/Insider2.31%
Public Company1.09%
Private Company0.47%
Insurance Company0.17%
Other12.12%
主要股东 截至 2026-06-30
Frazier Life Sciences Management, LP
7.40% · 7.61M 股
TPG Capital, L.P.
6.68% · 6.88M 股
venBio LLC
5.75% · 5.91M 股
Logos Global Management, L.P.
5.27% · 5.43M 股
BlackRock
5.12% · 5.27M 股
Franklin Resources
4.81% · 4.95M 股
Paradigm Biocapital Advisors LP
4.81% · 4.95M 股
Vanguard Capital Management, LLC
4.60% · 4.73M 股
Propel Bio Management, LLC
3.92% · 4.03M 股
Marshall Wace LLP
3.66% · 3.77M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 36次买入 · 9次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Thomas King | Director | 0.31% |
| Richard A. Stewart | Executive Chairperson | 0.20% |
| Mark Oki | Chief Financial Officer | 0.12% |
| Jaime Xinos | Executive Vice President of Commercial | 0.07% |
| Craig Donnelly | Executive Vice President of CMC & Regulatory CMC | 0.05% |
| Mark Rubinstein | Head of Medical Affairs | 0.04% |
| Jerry Wan | Principal Accounting Officer | 0.03% |
| James Coulter | -- | -- |
| Cindy Jacobs | President, Chief Medical Officer & Director | -- |
| Stuart Duty | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-04 | Benjamin Halladay | Chief Financial Officer | Other Derivative Acquisition | +200,000 | $7.01 |
| 2026-08-18 | Richard A. Stewart | Executive Chairperson | Open Market Disposition | -20,626 | $8.49 |
| 2026-07-26 | Richard A. Stewart | Executive Chairperson | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Richard A. Stewart | Executive Chairperson | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Jeffrey S. Farrow | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Jeffrey S. Farrow | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Aaron Royston | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Aaron Royston | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Thomas Sellig | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Thomas Sellig | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Nancy Phelan | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Nancy Phelan | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Reid Waldman | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Reid Waldman | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-07-26 | Christopher Martin | Director | Other Derivative Acquisition | +16,700 | -- |
| 2026-07-26 | Christopher Martin | Director | Other Derivative Acquisition | +25,000 | $6.18 |
| 2026-05-28 | Jeffrey S. Farrow | Director | Other Derivative Acquisition | +47,250 | $5.24 |
| 2026-05-28 | Reid Waldman | Director | Other Derivative Acquisition | +47,250 | $5.24 |
| 2026-05-10 | Christopher Martin | Director | Other Derivative Acquisition | +47,250 | $5.59 |
| 2026-04-17 | Andrew Goldberg | Chief Executive Officer | Other Derivative Acquisition | +1,800,965 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:43:54 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
阿奇夫生命科学 讨论区 0 条评论